Durability of clinical benefit with Stanford Neuromodulation Therapy (SNT) in treatment-resistant depression
Background: Depression, the leading cause of disability worldwide, is a chronic disease characterized by a relapsing-remitting course. Acute treatments such as electroconvulsive therapy, ketamine, and repetitive transcranial magnetic stimulation are often effective at initiating remission, but relap...
Saved in:
| Main Authors: | Andrew D. Geoly, Katy H. Stimpson, Flint M. Espil, Brandon S. Bentzley, Nolan R. Williams |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Brain Stimulation |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1935861X25000877 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Durability of clinical benefit with Stanford Neuromodulation Therapy (SNT) in treatment-resistant depression: assessment of sustained remission and response following index treatment
by: Andrew D. Geoly, M.S, et al.
Published: (2025-07-01) -
An Open-Label Pilot Trial to Assess the Feasibility of Using the Magnus Neuromodulation System with Stanford Accelerated Intelligent Neuromodulation Therapy (SAINTⓇ) as a Personalized Continuation Therapy for Depression
by: Katy H. Stimpson, et al.
Published: (2025-07-01) -
Fast Depressive Symptom Improvement in Bipolar Disorder Type 1 after Stanford Accelerated Intelligent Neuromodulation Therapy: A Two-Site Feasibility and Safety Open Label Trial
by: Jorge Almeida, et al.
Published: (2025-01-01) -
Reduction of Beta Band Activity in the Dorsolateral Prefrontal Cortex and Subgenual Anterior Cingulate Cortex After Stanford Neuromodulation Therapy in Treatment-Resistant Depression
by: Masataka Wada, et al.
Published: (2025-01-01) -
Temporal Complexity as a Biomarker for Antidepressant Response: Insights from the Distance-Scaled Complexity Index (DSCI) in Stanford Neuromodulation Therapy
by: Andrew Geoly, et al.
Published: (2025-01-01)